1. This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More.
  2. Dear Guest, we realise advertising is annoying, it is however necessary to help us be a sustainable resource for all, if you want to go advert free then please use the following link to subscribe for £5 a month: Click here
    Dismiss Notice

(MTPH) Midatech Pharma Chat

Discussion in 'General Share Chat (MTPH)' started by Inspiration, Jan 2, 2018.

  1. Inspiration

    Inspiration Moderator Moderator

    Messages:
    2,349
    Reputation:
    788
    2 January 2018

    Midatech Pharma PLC

    ("Midatech" or the "Company")


    Midatech enters into a Loan Agreement with MidCap Financial


    Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, is pleased to announce that it has entered into a four-year senior secured loan agreement with MidCap Financial of up to $15 million (the "Facility").


    Midatech has received an initial tranche of $7 million. The issuance of further tranches under the Facility is dependent on clinical development milestones set out for MTD201 and MTX110. The funds will be used to support progression towards these and other value-driving product milestones.


    Commenting on the agreement, Dr Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "This agreement allows us to continue the clinical development of key products. With the extensive due diligence that was required, it also indicates significant support in Midatech's future. With our lead programmes heading towards potentially significant, value-driving inflection points in 2018, and the continued progress of our R&D pipeline and US commercial activities, this is an exciting time for the business."
     
  2. Inspiration

    Inspiration Moderator Moderator

    Messages:
    2,349
    Reputation:
    788
    > 50% held by Pension funds and investment companies:

    Woodford 20%
    L&G 16.67%
    City Financial Investment 6% (a global investment group with $3.4bn assets under management)
    Wings Establishment 5%
    Hargreave Hale 4.9%

    Directors heavily invested.

    4-year senior secured loan agreement with MidCap Financial of up to $15 million
    Midatech has received an initial tranche of $7 million.
    The issuance of further tranches under the Facility is dependent on clinical development milestones set out for MTD201 and MTX110

    3 key projects with "value inflection points" over next 18 months (i.e. end March 2019) & potential long term value via Midatech's US commercial arm
    * £6m raised via placing at 50p per share Sept 17
    * £2m possibly via open offer to existing investors
    cash will be used to:
    1) accelerate the progress of MTD201, also known as Q-Octreotide, a long-acting treatment for a hormone disorder acromegaly and metastatic carcinoid tumours. Specifically, it will fund a study that compares the drug’s performance with Sandostatin, the current standard of care.
    2) Also receiving financial backing will be MTX110, being developed for use in a rare brain tumour disease suffered by children called diffuse pontine glioma. It is ready to go into its first in-human study.
    3) funds will be set aside for MTD119, a targeted therapy using gold nanoparticle technology for a form of liver cancer called hepatocellular carcinoma. An investigational new drug programme is currently underway with a first-in-human study set for the second-half of 2018.

    Results to 30.6.17
    Revenues up 42% year-on-year to £5.39mln,
    Loss from operations was just over £10mln following a £10.18mln cash outflow.
    At June 30, the company’s cash = £6.19m

    Year high 144p Jan 17, Year low 36p Dec 17. Current sp 40p.
     
    stockman likes this.
  3. ezglide

    ezglide Demi God of BlueShare

    Messages:
    1,061
    Reputation:
    1,126
    Why is Hargreaves Lansdown showing the share price in dollars ?
     
  4. Inspiration

    Inspiration Moderator Moderator

    Messages:
    2,349
    Reputation:
    788
    26 February 2019


    Midatech Pharma PLC

    ("Midatech" or the "Company")


    Finalisation of Strategic Investment and Licence Agreement

    Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to confirm that further to the announcement made by the Company on 29 January 2019 and following the approval at yesterday's general meeting by shareholders of the strategic investment by China Medical Systems Holdings Limited group ("CMS") and A&B (HK), the licence agreement entered into by the Company and CMS is now formally in force.

    The strategic investment by CMS and A&B (HK), comprised an £8m subscription in Midatech, for in aggregate 207,792,206 Ordinary Shares at a price of 3.85 pence per share. The Subscription Shares were admitted to trading on AIM today alongside the Placing Shares and Open Offer Shares.

    From a Midatech product perspective, as stipulated in the licence agreement, CMS has rights to develop and commercialize the Company's pipeline of products (including any products which are in or enter into pre-clinical or clinical development within a period of three years) in Greater China and certain South East Asian countries excluding Japan and South Korea (the "CMS Territory") in perpetuity. Subject to certain milestones being achieved, the Company will be entitled to receive regulatory and sales-based milestone payments as well as royalty payments.

    From a Midatech technology platform perspective the licence agreement permits CMS to identify its own potential product opportunities and, if agreed by Midatech, CMS will be entitled to carry out such development in China with initial assistance from Midatech which will be funded by CMS through a technology transfer fee payable to the Company by CMS. If such products obtain approval, CMS will retain the rights specific to such developed products and will license the Company to commercialize them outside the CMS Territory in the rest of the world.

    China Medical System Holdings Limited (HKG: 0867), is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China. CMS has established the diversified product introduction strategies to constantly provide competitive products and services to fulfil the unmet medical needs of the China market, as well as to sustain the momentum for its future development. CMS has a fully-covered nationwide promotional network, mainly focusing on academic promotion. As at 30 June 2018, CMS covered over 48,000 hospitals and medical institutions across China.

    The collaboration provides Midatech with a key strategic partnership in China and South East Asia, access to the significant Chinese market, substantial investment and funds for Midatech's current key programs, as well as additional CMS funded opportunities for the Company's technology platforms Q-Sphera, MidaSolve, and MidaCore.

    Dr Craig Cook, Chief Executive Office of Midatech Pharma, said: "We are delighted to finalise the licence agreement with China Medical Systems, a leading Hong Kong based Chinese pharmaceutical company. This is a key collaboration for Midatech that provides a strong endorsement of our technologies and pipeline whilst establishing a solid foundation for a successful and ambitious long-term partnership. The agreement will enable development of current and new products and extend our reach to the important markets of China and South East Asia. We look forward to developing this collaboration with CMS."

    Mr Lam Kong, Chairman and Chief Executive Officer of CMS, said: "We are excited to work with Midatech and the strategic investment and licence agreement is testament to our confidence in the value of the Midatech product pipeline and technologies, and our commitment to the partnership. We look forward to a fruitful relationship with Midatech as we contribute to the development of its innovative pipeline of products as we incorporate them into the extensive CMS portfolio."

    The capitalised terms not otherwise defined in the text of this announcement are as set out in the circular to shareholders dated 5 February 2019.
     
  5. Inspiration

    Inspiration Moderator Moderator

    Messages:
    2,349
    Reputation:
    788

Share This Page